drugset / Trial / NCT04902872
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
Timeline
- Start
- 2021-05-03
- Primary completion
- 2025-06-24
- Completion
- 2025-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBX-12 | Other / unclassified | — | — |